Header Logo

Connection

Gabriel Pardo to Insurance Claim Review

Back to Details
This is a "connection" page, showing publications Gabriel Pardo has written about Insurance Claim Review.
Gabriel Pardo
Connection Strength
0.186
Insurance Claim Review
  1. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. J Manag Care Spec Pharm. 2021 May; 27(5):639-649.
    View in: PubMed
    Score: 0.186
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.